Seurat Therapeutics gets $500K for its migraine-fighting nasal spray
A Chicago-based medical startup that wants to stop migraines using a nasal spray received more funding this week to continue its research.
Seurat Therapeutics, a biotech startup founded within the University of Chicago, received a $500,000 grant from the National Institute of Neurological Disorders and Stroke.
The funding will help the startup continue testing its product, a nasal spray that aims to stop the cause of migraines. The funding comes after the company raised $750,000 in seed funding…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Tatiana Walk-Morris Source Type: news
More News: Biotechnology | Brain | Funding | Grants | Headache | Health Management | Migraine | Neurology | Pharmaceuticals | Stroke